|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| 06:11am | Zymeworks expands beyond cancer with $929 million Theravance acquisition | RE |
| 04:42am | RBC ups Central Asia Metals to 'sector perform' | AN |
Business description: GlaxoSmithKline plc
- pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%);
- OTC and parapharmaceutical medicine (30.7%);
- vaccines (28%).
Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Sales by Activity: GlaxoSmithKline plc
| Fiscal Period: December | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) | 2025 (GBP) |
|---|---|---|---|---|---|
Commercial Operations | - | 29.32B | 30.33B | 31.38B | 32.67B |
Consumer Healthcare | 9.61B | - | - | - | - |
Vaccines | 6.78B | - | - | - | - |
Pharmaceuticals | 17.73B | - | - | - | - |
Geographical breakdown of sales: GlaxoSmithKline plc
| Fiscal Period: December | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) | 2025 (GBP) |
|---|---|---|---|---|---|
United States (US) | 15.09B | 14.54B | 15.82B | 16.38B | 16.86B |
Rest of World | 18.05B | 14.09B | 13.82B | 14.28B | 8.28B |
Europe | - | - | - | - | 6.85B |
United Kingdom (UK) | 975M | 695M | 693M | 708M | 683M |
Executive Committee: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 | |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 2022-01-18 |
Composition of the Board of Directors: GlaxoSmithKline plc
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
Charles Bancroft
BRD | Director/Board Member | 66 | 2020-04-30 |
Anne Beal
BRD | Director/Board Member | 63 | 2021-05-05 |
Harry Dietz
BRD | Director/Board Member | 68 | 2021-12-31 |
Vishal Sikka
BRD | Director/Board Member | 59 | 2022-07-17 |
| Director/Board Member | 68 | 2022-08-31 | |
Julie Brown
BRD | Director/Board Member | 64 | 2023-04-30 |
Wendy Becker
BRD | Director/Board Member | 60 | 2023-09-30 |
Holdings: GlaxoSmithKline plc
| Name | Stocks | % | Valuation |
|---|---|---|---|
| 127,054,524 | 75% | 2 954 M $ | |
| 263,029,794 | 82.59% | 335 M $ | |
HALEON PAKISTAN LIMITED 85.79% | 100,423,259 | 85.79% | 283 M $ |
CRISPR THERAPEUTICS AG 3.34% | 3,220,627 | 3.34% | 181 M $ |
WAVE LIFE SCIENCES LTD. 9.48% | 18,245,691 | 9.48% | 120 M $ |
BIONTECH SE 0.37% | 889,824 | 0.37% | 85 M $ |
VIR BIOTECHNOLOGY, INC. 5.07% | 8,550,954 | 5.07% | 82 M $ |
IDEAYA BIOSCIENCES, INC. 1.52% | 1,333,333 | 1.52% | 39 M $ |
LYELL IMMUNOPHARMA, INC. 6.48% | 1,512,659 | 6.48% | 26 M $ |
| 340,434 | 0.27% | 26 M $ |
Company details: GlaxoSmithKline plc
Group companies: GlaxoSmithKline plc
| Name | Category and Sector |
|---|---|
GlaxoSmithKline IHC Ltd.
 GlaxoSmithKline IHC Ltd. Regional BanksFinance Provides banking services |
Regional Banks
|
GlaxoSmithKline Ltd.
 GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a Chinese company. 'The company is based in Hong Kong, Hong Kong. |
Pharmaceuticals: Major
|
GlaxoSmithKline Ltd.
GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a Chinese company. 'The company is based in Hong Kong, Hong Kong. |
Pharmaceuticals: Major
|
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products |
Biotechnology
|
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products |
Biotechnology
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.67% | +11.55% | +57.71% | +164.68% | 1,077B | |
| +1.25% | +11.32% | +68.56% | +56.90% | 613B | |
| +0.75% | +11.04% | +37.59% | +91.70% | 448B | |
| +1.86% | +4.85% | +28.17% | +22.04% | 332B | |
| -0.14% | +7.58% | +41.28% | +27.25% | 293B | |
| -0.06% | +4.92% | +31.23% | +41.59% | 286B | |
| -0.96% | +4.98% | -28.37% | -40.96% | 215B | |
| +0.43% | +4.22% | +28.67% | +62.44% | 193B | |
| -1.42% | +0.82% | +13.56% | +65.64% | 159B | |
| Average | +0.37% | +7.97% | +30.93% | +54.59% | 401.79B | |
| Weighted average by Cap. | +0.86% | +9.35% | +42.32% | +81.37% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
- Company GlaxoSmithKline plc
Select your edition
All financial news and data tailored to specific country editions
